HC Wainwright Raises PT to $100, Maintains Buy Rating on Rhythm Pharmaceuticals.

HC Wainwright Raises PT to $100, Maintains Buy Rating on Rhythm Pharmaceuticals.

In a recent update, HC Wainwright has raised its price target for Rhythm Pharmaceuticals (NASDAQ: RYTM) to $100, while maintaining its "Buy" rating on the stock [2]. This move comes amidst a flurry of positive analyst ratings and increased institutional interest in the biopharmaceutical company.

HC Wainwright's latest assessment follows a string of positive analyst reports. Wells Fargo, Canaccord Genuity, Stifel Nicolaus, Guggenheim, and Leerink Partners have all raised their price targets and maintained or upgraded their ratings on Rhythm Pharmaceuticals in recent months [1]. The company has seen its 12-month price target average increase to $105.5, with a high estimate of $135.00 and a low estimate of $84.00 [2].

Rhythm Pharmaceuticals reported a 25.9% increase in revenue to $37.72 million in its latest quarter, despite missing earnings expectations. The company's lead product candidate, IMCIVREE, continues to attract attention, and the company's focus on rare neuroendocrine diseases positions it as a key player in this niche market [1].

Institutional investors have also shown increased interest in Rhythm Pharmaceuticals. BI Asset Management, State of Wyoming, GF Fund Management, CWM LLC, and Mirae Asset Global Investments have all recently acquired or increased their holdings in the company [1].

Despite these positive developments, Rhythm Pharmaceuticals faces challenges, including a negative return on equity of 739.62% and a negative net margin of 123.26% in its latest quarter [1]. However, the company's focus on innovative treatments for rare diseases and its strong pipeline of product candidates position it as a promising investment opportunity for those willing to take on higher risk.

References:
[1] https://www.marketbeat.com/instant-alerts/rhythm-pharmaceuticals-inc-nasdaqrytm-receives-consensus-rating-of-buy-from-analysts-2025-08-01/
[2] https://www.benzinga.com/insights/analyst-ratings/25/08/46928958/12-analysts-have-this-to-say-about-rhythm-pharmaceuticals